Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.verified

RXRX

Price:

$6.64

Market Cap:

$1.89B

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; ...[Read more]

Industry

Biotechnology

IPO Date

2021-04-16

Stock Exchange

NASDAQ

Ticker

RXRX

The Enterprise Value as of November 2024 (TTM) for Recursion Pharmaceuticals, Inc. (RXRX) is 1.50B

According to Recursion Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.50B. This represents a change of -9.62% compared to the average of 1.66B of the last 4 quarters.

Recursion Pharmaceuticals, Inc. (RXRX) Historical Enterprise Value (quarterly & annually)

How has RXRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Recursion Pharmaceuticals, Inc. over the last ten years is 2.17B. The current 1.50B Enterprise Value has changed 6.80% with respect to the historical average. Over the past ten years (40 quarters), RXRX's Enterprise Value was at its highest in in the June 2021 quarter at 4.43B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

2.17B

Median

2.64B

Minimum

854.49M

Maximum

2.93B

Recursion Pharmaceuticals, Inc. (RXRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Recursion Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 99.57%

Maximum Annual Enterprise Value = 2.93B

Minimum Annual Increase = -67.67%

Minimum Annual Enterprise Value = 854.49M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.71B99.57%
2022854.49M-67.67%
20212.64B-3.46%
20202.74B-6.58%

Recursion Pharmaceuticals, Inc. (RXRX) Average Enterprise Value

How has RXRX Enterprise Value performed in the past?

The current Enterprise Value of Recursion Pharmaceuticals, Inc. (RXRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

1.73B

5-year avg

2.17B

10-year avg

2.17B

Recursion Pharmaceuticals, Inc. (RXRX) Enterprise Value vs. Peers

How is RXRX’s Enterprise Value compared to its peers?

Recursion Pharmaceuticals, Inc.’s Enterprise Value is greater than Absci Corporation (408.11M), greater than Affimed N.V. (49.52M), greater than Sana Biotechnology, Inc. (796.24M), greater than Relay Therapeutics, Inc. (867.37M), greater than Immix Biopharma, Inc. (20.49M), greater than CNS Pharmaceuticals, Inc. (2.61M), greater than Hepion Pharmaceuticals, Inc. (1.72M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), greater than eFFECTOR Therapeutics, Inc. (3.64M), greater than Enveric Biosciences, Inc. (636.29K), greater than CohBar, Inc. (-4506335.00), greater than Ocean Biomedical, Inc. (42.20M), greater than Day One Biopharmaceuticals, Inc. (1.07B), greater than Acumen Pharmaceuticals, Inc. (137.49M), greater than X4 Pharmaceuticals, Inc. (20.60M), greater than Inozyme Pharma, Inc. (308.76M), greater than VectivBio Holding AG (848.58M),

Build a custom stock screener for Recursion Pharmaceuticals, Inc. (RXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recursion Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Recursion Pharmaceuticals, Inc. (RXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Recursion Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Recursion Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Recursion Pharmaceuticals, Inc. (RXRX)?

What is the 3-year average Enterprise Value for Recursion Pharmaceuticals, Inc. (RXRX)?

What is the 5-year average Enterprise Value for Recursion Pharmaceuticals, Inc. (RXRX)?

How does the current Enterprise Value for Recursion Pharmaceuticals, Inc. (RXRX) compare to its historical average?